Psych · Old age psychiatry — Alzheimer disease
Alzheimer disease
Also known as Alzheimer's disease · AD dementia · Major NCD due to Alzheimer disease · Dementia of Alzheimer type · Probable Alzheimer disease · Senile dementia of the Alzheimer type
Exam-exhaustive fellowship reference on Alzheimer disease — NIA-AA 2011 probable/possible clinical criteria; continuum from preclinical and MCI-due-to-AD to dementia; careful ATN biomarker research framing; amyloid/tau/cholinergic pathophysiology; assessment with collateral and cognitive screens; AChEI and memantine doses, titration, monitoring and DOMINO-AD; BPSD link with non-drug first line and antipsychotic mortality caution; capacity, care planning, and disposition. FRANZCP-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Acute fluctuating confusion on known Alzheimer disease — treat as delirium until proven otherwise; search infection, pain, constipation, retention, drugs, metabolic causes
- Bradycardia, syncope, or significant conduction disease before or during cholinesterase inhibitors — ECG review, hold drug, seek medical advice
- Severe aggression or psychosis with risk of harm — safety and medical exclusion first; antipsychotics only time-limited last line with explicit mortality counselling
- Rapidly progressive course over weeks — widen differential (CJD, autoimmune, space-occupying, toxic-metabolic); do not assume typical AD
- Unsafe driving, wandering, fire risk, or financial exploitation — capacity and risk management, not a cognitive score alone
- Young-onset or strong family history — specialist pathway; do not routine-test genes without counselling
Meet the patient
A 74-year-old retired schoolteacher is brought in by her son. For two years she has asked the same three questions on every phone call. She still cooks, but the gas has been left on twice, and last month she paid the same electricity bill four times.[1]
Her MMSE is 27 out of 30, and on that number alone she has twice been reassured that this is normal ageing. Nobody has asked the son what she used to be able to do, and nobody has run a screen that taxes executive and visuospatial function.[8][9]
Two exam questions are now live. Is 27 out of 30 reassuring? And what exactly goes in the letter — and what do you start? Everything below answers both at consultant depth.[1][8][9]
References20ShowHide
- [1]McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement, 2011.PMID 21514250
- [2]Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement, 2011.PMID 21514249
- [3]Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement, 2011.PMID 21514248
- [4]Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease Alzheimers Dement, 2018.PMID 29653606
- [5]Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Alzheimers Dement, 2024.PMID 38934362
- [6]Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol, 2007.PMID 17616482
- [7]Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet, 2020.PMID 32738937
- [8]Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res, 1975.PMID 1202204
- [9]Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc, 2005.PMID 15817019
- [10]Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology, 1994.PMID 7991117
- [11]Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease N Engl J Med, 2003.PMID 12672860
- [12]Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA, 2004.PMID 14734594
- [13]Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease N Engl J Med, 2012.PMID 22397651
- [14]Birks JS, Harvey RJ Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst Rev, 2018.PMID 29923184
- [15]McShane R, Westby MJ, Roberts E, et al. Memantine for dementia Cochrane Database Syst Rev, 2019.PMID 30891742
- [16]Kales HC, Gitlin LN, Lyketsos CG Assessment and management of behavioral and psychological symptoms of dementia BMJ, 2015.PMID 25731881
- [17]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
- [18]Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease N Engl J Med, 2006.PMID 17035647
- [19]Appelbaum PS, Grisso T Assessing patients' capacities to consent to treatment N Engl J Med, 1988.PMID 3200278
- [20]Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition Am J Psychiatry, 2007.PMID 18340692